At Editas Medicine, we are harnessing the potential of CRISPR gene editing to develop medicines for people living with serious diseases
Cambridge, MA and Boulder, CO
- Tweets 724
- Following 126
- Followers 8,348
- Likes 33
Last week, Editas participated in fireside chats at the Wells Fargo Healthcare Conference and Cantor Global Healthcare Conference, sharing updates on EDIT-401 and connecting with the wider healthcare and investment communities. Listen here: bit.ly/4r3c2d4. #invivo
332
Tomorrow, we’ll be participating in a fireside chat at the 2026 Cantor Global Healthcare Conference at 3:55 p.m. ET. Tune in here: bit.ly/4dbvZbP.
#geneediting #cardiovasculardisease #firesidechat
1
1
341
We’re thrilled to welcome Dan Ory, M.D., as Chief Medical Officer at Editas Medicine. Dr. Ory brings decades of experience in cardiovascular disease, genetic medicines, and clinical development as we advance EDIT-401 toward the clinic. Read more: bit.ly/4y1Mwb3 #invivo
1
342
#NEWS: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer. Read the press release for details: bit.ly/4y1Mwb3.
#geneediting #cardiovasculardisease #leadership
2
416
On Tuesday, we’ll be participating in a fireside chat at the Wells Fargo Healthcare Conference at 4:30 p.m. ET. Tune in here: bit.ly/4i4kbvA.
#invivo #cardiovasculardisease #firesidechat
2
350
#NEWS Editas Medicine to Participate in Upcoming Investor Conferences. Read the press release here: bit.ly/4yhw1as. #geneediting #cardiovasculardisease #invivo
3
377
Our President & CEO Gilmore O’Neill discusses the evolution of gene editing, the potential of in vivo approaches, and the opportunity to develop durable, potentially one-time therapies for patients with serious diseases: Read here: bit.ly/4qnl7Nr. #biotech #leadership
6
517
It was a pleasure to attend the @thecsanz 2026 Scientific Meeting in Sydney, connecting with experts advancing cardiovascular research. We’re grateful to share our work as we continue advancing EDIT-401 toward the clinic Read our e-poster here: bit.ly/4z7RlQZ. #CSANZ2026
4
412
Earlier this week, Editas Medicine announced second quarter 2026 results and business updates. Read the full press release here: bit.ly/4wdJgr4.
#genediting #biotech #cardiovasculardisease #earnings
1
1
521
Welcome Patrick Ellinor, M.D., Ph.D., to the Editas Medicine Board of Directors. A recognized leader in cardiovascular medicine and genetics, Dr. Ellinor brings extensive experience as we advance EDIT-401 toward the clinic: bit.ly/3RVJ5Tk. #cardiovasculardisease #invivo
2
580
#NEWS Editas Medicine Announces Second Quarter 2026 Results and Business Updates. Read the full press release here: bit.ly/4hQCOTo
#cardiovasculardisease #invivo #earnings
1
2
497
#NEWS Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D. Read the full press release here: bit.ly/4fVpSJu #geneediting #cardiovasculardisease #boardofdirectors
2
648
Thank you to everyone who joined us last week at Cell & Gene Therapy World Asia 2026. It was a pleasure connecting with colleagues from across the cell and gene therapy community and sharing insights on the value of early CMC integration. #CGTAsia2026 #CGTWA2026 #CMC #biotech
3
411
It was great to participate in this year’s European Congress on Biotechnology. We enjoyed connecting with researchers, innovators, and industry leaders from across the biotechnology community to discuss the future of genetic medicines. #ECB2026 #biotechnology #geneediting #invivo
3
438
Last week, Team Editas participated in the annual J.P. Morgan Corporate Challenge. It was a great opportunity to connect with colleagues and celebrate teamwork beyond the workplace. Thank you to everyone who participated and represented Editas Medicine!
#JPMCorporateChallenge
1
473
Next week, we'll present at Cell & Gene Therapy World Asia 2026 with our session, "Designing for Development: The Role of Early CMC Integration in Product Lifecycle Success." See you in Singapore! #CGTAsia2026 #CGTWA2026 #CellAndGeneTherapy #CMC #Biomanufacturing
2
409
Join us next week at the European Congress on Biotechnology for our keynote lecture, "A Walk Through the Evolution of Genetic Medicines," exploring advances in gene editing, delivery, and manufacturing that are shaping the future of genetic medicines.
#ECB2026 #biotechnology
4
426
Next week, our President & CEO, Gilmore O’Neill, will join fellow industry leaders at the Longwood Healthcare Leaders MIT CEO 2026 Meeting for a panel on “Pipeline Prioritization.” We look forward to an insightful discussion! #LongwoodHealthcareLeaders #MITCEO #biotech
1
285
We’re excited to attend the 2026 National Lipid Association Sessions in Chicago this week, where we’ll present preclinical data on our lead in vivo development candidate, EDIT-401.
#NLASessions #cardiovasculardisease #invivo #geneediting
1
2
263
Yesterday, Editas Medicine President & CEO, Gilmore O’Neill, presented at the 2026 Jefferies Global Healthcare Conference, where he highlighted the latest updates on the EDIT-401 program. Listen to the presentation here: bit.ly/4nqnhuq. #Jefferies2026
1
1
6
398